Premium Osimertinib India Generic: Advanced Targeted Therapy for EGFR-Mutant NSCLC
Ensuring global access to gold-standard oncology care. Clinically bioequivalent Osimertinib generics manufactured under strict WHO-GMP standards for maximum purity and patient outcomes.
Drug Overview
Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Unlike first- and second-generation TKIs, Osimertinib is specifically designed to target the T790M mutation, which is the primary cause of resistance to earlier therapies in non-small cell lung cancer (NSCLC).
By binding irreversibly to the mutated EGFR, Osimertinib shuts down the signaling pathways that drive tumor growth and proliferation, significantly extending progression-free survival (PFS) and overall survival (OS) in patients with advanced stage EGFR-mutant lung cancer.
| Feature | Original Brand (Tagrisso) | Osimertinib India Generic |
|---|---|---|
| Active Ingredient | Osimertinib Mesylate | Identical Osimertinib Mesylate |
| Bioequivalence | Reference Standard | Clinically Bioequivalent |
| Certification | FDA / EMA | WHO-GMP / USFDA / EDQM |
| Cost Efficiency | Premium Pricing | Highly Cost-Effective |
| Purity Level | ≥ 99% | ≥ 99% (HPLC Verified) |
Why Choose India Generic
- WHO-GMP Certified Facilities: Our partner manufacturers operate in facilities audited by the World Health Organization (WHO) and the USFDA.
- Unmatched Cost-Effectiveness: Reduce the cost of treatment by up to 70-90% without compromising on efficacy.
- Scale of Production: Ensuring a stable, uninterrupted supply of Osimertinib regardless of global market fluctuations.
- Rigorous Quality Control: Each shipment undergoes strict HPLC testing to verify chemical purity.
- GDM Network Assurance: Ensuring cold-chain integrity and rapid customs clearance.
- Clinically Proven Bioequivalence: Generic versions mirror the pharmacokinetic profile of the original brand.
Member Manufacturers Directory
| Company | Strengths Available | Monthly Capacity | MOQ | Certification | Action |
|---|---|---|---|---|---|
| Cipla Ltd | API Stability | 500k+ | 100 Boxes | WHO-GMP | Quote |
| Natco Pharma | Oncology Spec | 300k+ | 50 Boxes | WHO-GMP | Quote |
| Hetero Labs | High Volume | 1M+ | 200 Boxes | USFDA | Quote |
| Sun Pharma | R&D | 400k+ | 100 Boxes | USFDA | Quote |
Price & Supply Information
Wholesale rates range from USD $120 to $350 per box. Lead time: 7-14 business days via temperature-controlled air freight.
Clinical Data & FAQ
Q: Is Osimertinib India Generic as effective as the original?
A: Yes. Clinical bioequivalence studies show identical peak plasma concentration and therapeutic effect on EGFR T790M mutation.
Related Products
Contact: support@abc.com / contact@er-neng.com